{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiegh4rfxu6jvafdicwop5kqzle77nb27idwfrifqeo4bnwcnoncwi",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mouzeajgrmc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiakfojelf5zbqe2ayeokeotthzkcdqgitpfejd57mbtzt7igtnjpu"
    },
    "mimeType": "image/jpeg",
    "size": 76498
  },
  "path": "/2026/06/22/definium-lsd-dt120-major-depression-phase-3-data/?utm_campaign=rss",
  "publishedAt": "2026-06-22T11:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "Clinical trials",
    "drug development",
    "Pharmaceuticals",
    "psychedelics",
    "STAT+"
  ],
  "textContent": "Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.",
  "title": "STAT+: Definium LSD therapy helped patients with major depression in late-stage trial",
  "updatedAt": "2026-06-22T00:04:01.000Z"
}